Recent News

• 05.24.2025 - Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
• 05.20.2025 - Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
• 05.12.2025 - Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.07.2025 - Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
• 05.05.2025 - Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
• 04.23.2025 - Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
• 04.23.2025 - Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Recent Filings

• 05.22.2025 - 8-K Current report
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2025 - 144 Report of proposed sale of securities
• 05.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 8-K Current report
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities